Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein

Craig C. Hofmeister, Xiaoxia Yang, Flavia Pichiorri, Ping Chen, Darlene M. Rozewski, Amy J. Johnson, Seungsoo Lee, Zhongfa Liu, Celia L. Garr, Erinn M. Hade, Jia Ji, Larry J. Schaaf, Don M. Benson, Eric H. Kraut, William J. Hicks, Kenneth K. Chan, Ching Shih Chen, Sherif Farag, Michael R. Grever, John C. ByrdMitch A. Phelps

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Purpose: Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone. The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM. Patients and Methods: A phase I clinical trial was initiated for patients with relapsed myeloma with administration of oral lenalidomide on days 1 to 21 and CCI-779 intravenously once per week during a 28-day cycle. Pharmacokinetic data for both agents were obtained, and in vitro transport and uptake studies were conducted to evaluate potential drug-drug interactions. Results: Twenty-one patients were treated with 15 to 25 mg lenalidomide and 15 to 20 mg CCI-779. The maximum-tolerated dose (MTD) was determined to be 25 mg lenalidomide with 15 mg CCI-779. Pharmacokinetic analysis indicated increased doses of CCI-779 resulted in statistically significant changes in clearance, maximum concentrations, and areas under the concentration-time curves, with constant doses of lenalidomide. Similar and significant changes for CCI-779 pharmacokinetics were also observed with increased lenalidomide doses. Detailed mechanistic interrogation of this pharmacokinetic interaction demonstrated that lenalidomide was an ABCB1 (P-glycoprotein [P-gp]) substrate. Conclusion: The MTD of this combination regimen was 25 mg lenalidomide with 15 mg CCI-779, with toxicities of fatigue, neutropenia, and electrolyte wasting. Pharmacokinetic and clinical interactions between lenalidomide and CCI-779 seemed to occur, with in vitro data indicating lenalidomide was an ABCB1 (P-gp) substrate. To our knowledge, this is the first report of a clinically significant P-gp-based drug-drug interaction with lenalidomide.

Original languageEnglish
Pages (from-to)3427-3434
Number of pages8
JournalJournal of Clinical Oncology
Volume29
Issue number25
DOIs
StatePublished - Sep 1 2011

Fingerprint

P-Glycoprotein
Multiple Myeloma
Pharmacokinetics
Maximum Tolerated Dose
Drug Interactions
Plasma Cell Neoplasms
temsirolimus
lenalidomide
Clinical Trials, Phase I
Neutropenia
Pharmaceutical Preparations
Dexamethasone
Electrolytes
Fatigue
Oral Administration

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma : Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. / Hofmeister, Craig C.; Yang, Xiaoxia; Pichiorri, Flavia; Chen, Ping; Rozewski, Darlene M.; Johnson, Amy J.; Lee, Seungsoo; Liu, Zhongfa; Garr, Celia L.; Hade, Erinn M.; Ji, Jia; Schaaf, Larry J.; Benson, Don M.; Kraut, Eric H.; Hicks, William J.; Chan, Kenneth K.; Chen, Ching Shih; Farag, Sherif; Grever, Michael R.; Byrd, John C.; Phelps, Mitch A.

In: Journal of Clinical Oncology, Vol. 29, No. 25, 01.09.2011, p. 3427-3434.

Research output: Contribution to journalArticle

Hofmeister, CC, Yang, X, Pichiorri, F, Chen, P, Rozewski, DM, Johnson, AJ, Lee, S, Liu, Z, Garr, CL, Hade, EM, Ji, J, Schaaf, LJ, Benson, DM, Kraut, EH, Hicks, WJ, Chan, KK, Chen, CS, Farag, S, Grever, MR, Byrd, JC & Phelps, MA 2011, 'Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein', Journal of Clinical Oncology, vol. 29, no. 25, pp. 3427-3434. https://doi.org/10.1200/JCO.2010.32.4962
Hofmeister, Craig C. ; Yang, Xiaoxia ; Pichiorri, Flavia ; Chen, Ping ; Rozewski, Darlene M. ; Johnson, Amy J. ; Lee, Seungsoo ; Liu, Zhongfa ; Garr, Celia L. ; Hade, Erinn M. ; Ji, Jia ; Schaaf, Larry J. ; Benson, Don M. ; Kraut, Eric H. ; Hicks, William J. ; Chan, Kenneth K. ; Chen, Ching Shih ; Farag, Sherif ; Grever, Michael R. ; Byrd, John C. ; Phelps, Mitch A. / Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma : Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 25. pp. 3427-3434.
@article{5c902ce4f75944429ec229e934dbe065,
title = "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein",
abstract = "Purpose: Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone. The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM. Patients and Methods: A phase I clinical trial was initiated for patients with relapsed myeloma with administration of oral lenalidomide on days 1 to 21 and CCI-779 intravenously once per week during a 28-day cycle. Pharmacokinetic data for both agents were obtained, and in vitro transport and uptake studies were conducted to evaluate potential drug-drug interactions. Results: Twenty-one patients were treated with 15 to 25 mg lenalidomide and 15 to 20 mg CCI-779. The maximum-tolerated dose (MTD) was determined to be 25 mg lenalidomide with 15 mg CCI-779. Pharmacokinetic analysis indicated increased doses of CCI-779 resulted in statistically significant changes in clearance, maximum concentrations, and areas under the concentration-time curves, with constant doses of lenalidomide. Similar and significant changes for CCI-779 pharmacokinetics were also observed with increased lenalidomide doses. Detailed mechanistic interrogation of this pharmacokinetic interaction demonstrated that lenalidomide was an ABCB1 (P-glycoprotein [P-gp]) substrate. Conclusion: The MTD of this combination regimen was 25 mg lenalidomide with 15 mg CCI-779, with toxicities of fatigue, neutropenia, and electrolyte wasting. Pharmacokinetic and clinical interactions between lenalidomide and CCI-779 seemed to occur, with in vitro data indicating lenalidomide was an ABCB1 (P-gp) substrate. To our knowledge, this is the first report of a clinically significant P-gp-based drug-drug interaction with lenalidomide.",
author = "Hofmeister, {Craig C.} and Xiaoxia Yang and Flavia Pichiorri and Ping Chen and Rozewski, {Darlene M.} and Johnson, {Amy J.} and Seungsoo Lee and Zhongfa Liu and Garr, {Celia L.} and Hade, {Erinn M.} and Jia Ji and Schaaf, {Larry J.} and Benson, {Don M.} and Kraut, {Eric H.} and Hicks, {William J.} and Chan, {Kenneth K.} and Chen, {Ching Shih} and Sherif Farag and Grever, {Michael R.} and Byrd, {John C.} and Phelps, {Mitch A.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1200/JCO.2010.32.4962",
language = "English",
volume = "29",
pages = "3427--3434",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma

T2 - Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein

AU - Hofmeister, Craig C.

AU - Yang, Xiaoxia

AU - Pichiorri, Flavia

AU - Chen, Ping

AU - Rozewski, Darlene M.

AU - Johnson, Amy J.

AU - Lee, Seungsoo

AU - Liu, Zhongfa

AU - Garr, Celia L.

AU - Hade, Erinn M.

AU - Ji, Jia

AU - Schaaf, Larry J.

AU - Benson, Don M.

AU - Kraut, Eric H.

AU - Hicks, William J.

AU - Chan, Kenneth K.

AU - Chen, Ching Shih

AU - Farag, Sherif

AU - Grever, Michael R.

AU - Byrd, John C.

AU - Phelps, Mitch A.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Purpose: Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone. The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM. Patients and Methods: A phase I clinical trial was initiated for patients with relapsed myeloma with administration of oral lenalidomide on days 1 to 21 and CCI-779 intravenously once per week during a 28-day cycle. Pharmacokinetic data for both agents were obtained, and in vitro transport and uptake studies were conducted to evaluate potential drug-drug interactions. Results: Twenty-one patients were treated with 15 to 25 mg lenalidomide and 15 to 20 mg CCI-779. The maximum-tolerated dose (MTD) was determined to be 25 mg lenalidomide with 15 mg CCI-779. Pharmacokinetic analysis indicated increased doses of CCI-779 resulted in statistically significant changes in clearance, maximum concentrations, and areas under the concentration-time curves, with constant doses of lenalidomide. Similar and significant changes for CCI-779 pharmacokinetics were also observed with increased lenalidomide doses. Detailed mechanistic interrogation of this pharmacokinetic interaction demonstrated that lenalidomide was an ABCB1 (P-glycoprotein [P-gp]) substrate. Conclusion: The MTD of this combination regimen was 25 mg lenalidomide with 15 mg CCI-779, with toxicities of fatigue, neutropenia, and electrolyte wasting. Pharmacokinetic and clinical interactions between lenalidomide and CCI-779 seemed to occur, with in vitro data indicating lenalidomide was an ABCB1 (P-gp) substrate. To our knowledge, this is the first report of a clinically significant P-gp-based drug-drug interaction with lenalidomide.

AB - Purpose: Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone. The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM. Patients and Methods: A phase I clinical trial was initiated for patients with relapsed myeloma with administration of oral lenalidomide on days 1 to 21 and CCI-779 intravenously once per week during a 28-day cycle. Pharmacokinetic data for both agents were obtained, and in vitro transport and uptake studies were conducted to evaluate potential drug-drug interactions. Results: Twenty-one patients were treated with 15 to 25 mg lenalidomide and 15 to 20 mg CCI-779. The maximum-tolerated dose (MTD) was determined to be 25 mg lenalidomide with 15 mg CCI-779. Pharmacokinetic analysis indicated increased doses of CCI-779 resulted in statistically significant changes in clearance, maximum concentrations, and areas under the concentration-time curves, with constant doses of lenalidomide. Similar and significant changes for CCI-779 pharmacokinetics were also observed with increased lenalidomide doses. Detailed mechanistic interrogation of this pharmacokinetic interaction demonstrated that lenalidomide was an ABCB1 (P-glycoprotein [P-gp]) substrate. Conclusion: The MTD of this combination regimen was 25 mg lenalidomide with 15 mg CCI-779, with toxicities of fatigue, neutropenia, and electrolyte wasting. Pharmacokinetic and clinical interactions between lenalidomide and CCI-779 seemed to occur, with in vitro data indicating lenalidomide was an ABCB1 (P-gp) substrate. To our knowledge, this is the first report of a clinically significant P-gp-based drug-drug interaction with lenalidomide.

UR - http://www.scopus.com/inward/record.url?scp=80052756653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052756653&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.32.4962

DO - 10.1200/JCO.2010.32.4962

M3 - Article

C2 - 21825263

AN - SCOPUS:80052756653

VL - 29

SP - 3427

EP - 3434

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -